Perspectives in HIV Protease Inhibitors

  • John M. Leonard
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 394)


The therapy of HIV-1, the causative agent of AIDS, is limited today to a small number of different drugs, all of which are nucleoside analogues. Nucleoside analogues active against HIV are all inhibitors of reverse transcriptase (RT) and target primarily early events in the replication cycle of HIV. In vitro activity of these compounds has been confirmed by evidence of inhibition of HIV replication in vivo, although the clinical benefits of these compounds wane with time. Agents active against targets other than RT are necessary to expand and improve the pharmacopoeia for the treatment of HIV infection and AIDS. Specific inhibitors of the HIV protease promise to expand the options for the treatment of HIV infection.


Nucleoside Analogue Plasma Drug Level Human Immunodeficiency Virus Protease Peripheral Blood Mononuclear Cell Culture Active Human Immunodeficiency Virus 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Kohl NE, Emini EA, Schleif WA, et al. Active human immunodeficiency virus protease is required for viral infectivity. Proc Natl Acad Sci USA 1988; 85: 4686–90.PubMedCrossRefGoogle Scholar
  2. 2.
    Norbeck DW. Recent advances in anti-retroviral chemotherapy for AIDS. Annu Rep Med Chem 1989 1989; 25: 149–58.Google Scholar
  3. 3.
    Meek TD, Dreyer GB. HIV-1 protease as a potential target for anti-AIDS therapy. Ann NY Acad Sci 1990; 616: 41–53.PubMedCrossRefGoogle Scholar
  4. 4.
    Peng C, Ho BK, Chang TW, Chang NT. Role of human immunodeficiency virus type 1-specific protease in core protein maturation and viral infectivity. J Virol 1989; 63: 2550–6.PubMedGoogle Scholar
  5. 5.
    Le Grice SFJ, Mills J, Mous J. Active site mutagenesis of the AIDS virus protease and its alleviation by trans complementation. EMBO J 1988; 7: 2547–53.PubMedGoogle Scholar
  6. 6.
    Vacca JP, Guare JP, deSolms SJ, et al. L-687,908, a potent hydroxyethylene-containing HIV protease inhibitor. J Med Chem 1991; 34: 1225–8.PubMedCrossRefGoogle Scholar
  7. 7.
    Erickson J, Neidhart DJ, VanDrie J, et al. Design, activity, and 2.8 A crystal structure of a C2 symmetric inhibitor complexed to HIV-1 protease. Science 1990; 249: 527–33.PubMedCrossRefGoogle Scholar
  8. 8.
    Rosenberg SH, Kleinert HD, Stein HH, et al. Design of a well-absorbed renin inhibitor. J Med Chem 1991; 34: 469–71.PubMedCrossRefGoogle Scholar
  9. 9.
    Reedijk M, Boucher CAB, VBommel t, et al. The safety, pharmacokinetics and antiviral activity of A77003, a C2-symmetry based HIV protease inhibitor. Antimicrob Agents Chemother 1995; 39: 1559–1564.PubMedCrossRefGoogle Scholar
  10. 10.
    Data on file, Abbott Laboratories.Google Scholar
  11. 11.
    Kempf DJ, Marsh KC, Denissen JF, et al. ritonavir is a potent inhibitor of human immunodeficiency virus protease with high oral bioavailability.Google Scholar
  12. 12.
    Kageyama S, Anderson BD, Hoesterey BL, Hayashi H, Kiso Y, Flora KP and Mitsuya H. Antimicrob Agents Chemother 1994; 38: 1107–1111.PubMedCrossRefGoogle Scholar
  13. 13.
    Personal communication, G. Drusano.Google Scholar
  14. 14.
    Markowitz M, Mo H, Kempf DJ, et al. Selection and analysis of human immunodeficiency virus type 1 variants with increased resistance to ritonavir, a novel protease inhibitor. J Virol 1995; 69: 701–6.PubMedGoogle Scholar
  15. 15.
    Ho DD, Neumann AU, Perelson AS, Chen W, Leonard JM and Markowitz M. Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature 1995; 373: 123–6.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 1996

Authors and Affiliations

  • John M. Leonard

There are no affiliations available

Personalised recommendations